cetrelimab
cetrelimab: 10 clinical trials tracked.
cetrelimab evidence translation
What we can confirm
10 tracked trials
What it means
What to watch
Prepared research question
What is verified about cetrelimab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 2 study sponsors
Clinical Trials (10)
Phase 1 Study of Intratumoral Administration of JNJ-1761981 ER, an Extended Release Chemotherapy, in Participants With Solid Tumors
Primary endpoint: Part 1: Number of Participants with Adverse Events (AE) by Severity
A Phase II, Open Label, Multi-center Study of 89Zr-DF-Crefmirlimab for CD8 Positron Emission Tomography in Patients With Locally Advanced or Metastatic Solid Tumours
Primary endpoint: Whole body distribution of 89Zr-Df-crefmirlimab
Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors
Primary endpoint: Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)
A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-Small Cell Lung Cancer
Primary endpoint: Number of Participants with Adverse Events (AEs) by Severity
A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer
Primary endpoint: Part 1: Number of Participants With Dose Limiting Toxicity (DLT)
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer
Primary endpoint: Event-free Survival (EFS)
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy
Primary endpoint: Pathologic Complete Response (pCR) Rate
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Primary endpoint: Cohorts 1, 2, and 3: Overall Complete Response (CR) Rate
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy
Primary endpoint: Time from Randomization to the First Bladder Intact Event-free Survival (BI-EFS) event
A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Primary endpoint: Combination 1: Part 1: Number of Participants With Specified Toxicity